STOCK TITAN

Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Relay Therapeutics reports that Perceptive Life Sciences Master Fund, Perceptive Advisors LLC and Joseph Edelman each beneficially own 9,404,725 shares of Common Stock, representing 5.3% of the class.

Ownership is shown as shared voting and dispositive power for 9,404,725 shares. The filing cites 178,725,809 shares outstanding as of February 20, 2026 as the basis for percentage calculation.

Positive

  • None.

Negative

  • None.

Insights

Perceptive-affiliated entities list a 5.3% beneficial stake in Relay Therapeutics.

The filing shows the Master Fund directly holds 9,404,725 shares and that Perceptive Advisors and Joseph Edelman may be deemed beneficial owners through shared voting and dispositive power. The percentage is calculated against 178,725,809 shares outstanding as of February 20, 2026.

This is a disclosure of ownership under Schedule 13G; cash‑flow treatment and any planned transactions are not disclosed in the excerpt. Subsequent filings would show changes in position or voting arrangements.






75943R102

(CUSIP Number)
03/12/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:03/19/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:03/19/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:03/19/2026
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

What stake does Perceptive Advisors report in RELAY?

Perceptive Advisors is reported as beneficially owning 9,404,725 shares, equal to 5.3% of the class. The percentage uses 178,725,809 shares outstanding as of February 20, 2026, per the filing.

Who directly holds the shares listed in the Schedule 13G for RLAY?

The Schedule 13G states that Perceptive Life Sciences Master Fund, Ltd. directly holds 9,404,725 shares. Perceptive Advisors and Joseph Edelman are reported as investment manager and managing member respectively.

How is voting and dispositive power reported for these RLAY shares?

The filing shows shared voting power and shared dispositive power of 9,404,725 shares for each reporting person. Sole voting and sole dispositive power are reported as 0.

What outstanding share figure does the Schedule 13G use to calculate percentages?

The percentage ownership is based on 178,725,809 shares outstanding as of February 20, 2026, as cited from the issuer's Annual Report on Form 10-K filed February 26, 2026.

Does the Schedule 13G disclose any planned sales or purchases of RLAY stock?

No planned transactions are disclosed in the provided excerpt. The filing lists current beneficial ownership and voting/dispositive power but does not state any intentions to buy or sell shares.
Relay Therapeutics, Inc.

NASDAQ:RLAY

View RLAY Stock Overview

RLAY Rankings

RLAY Latest News

RLAY Latest SEC Filings

RLAY Stock Data

1.72B
145.74M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CAMBRIDGE